In last trading session, ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) saw 33.19 million shares changing hands with its beta currently measuring 0.40. Company’s recent per share price level of $0.41 trading at $0.05 or 11.48% at ring of the bell on the day assigns it a market valuation of $18.54M. That closing price of IPA’s stock is at a discount of -317.07% from its 52-week high price of $1.71 and is indicating a premium of 34.15% from its 52-week low price of $0.27. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.02 million shares which gives us an average trading volume of 7.30 million if we extend that period to 3-months.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
Upright in the green during last session for gaining 11.48%, in the last five days IPA remained trading in the green while hitting it’s week-highest on Thursday, 03/13/25 when the stock touched $0.41 price level, adding 5.42% to its value on the day. ImmunoPrecise Antibodies Ltd’s shares saw a change of -1.63% in year-to-date performance and have moved 1.25% in past 5-day. ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) showed a performance of -12.17% in past 30-days. Number of shares sold short was 2.19 million shares which calculate 0.75 days to cover the short interests.
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
This year revenue growth is estimated to rise 0.92% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.58M for the same. And 2 analysts are in estimates of company making revenue of 6.77M in the next quarter. Company posted 6.22M and 6.46M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.23% during past 5 years.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
Insiders are in possession of 5.27% of company’s total shares while institution are holding 4.17 percent of that, with stock having share float percentage of 4.40%. Investors also watch the number of corporate investors in a company very closely, which is 4.17% institutions for ImmunoPrecise Antibodies Ltd that are currently holding shares of the company. INGALLS & SNYDER LLC is the top institutional holder at IPA for having 1.3 million shares of worth $1.31 million. And as of 2024-06-30, it was holding 5.0209 of the company’s outstanding shares.
The second largest institutional holder is RENAISSANCE TECHNOLOGIES LLC, which was holding about 63910.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.2477 of outstanding shares, having a total worth of $64549.0.
